Located in Research Park, the new clinic offers multidisciplinary care from the College of Medicine, School of Social Work, and College of Health Professions and Sciences.
(0)
DGAP-News: AFFiRiS AG / Key word(s): Conference/Study
AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16th Annual Huntington s Disease Therapeutics Conference
27.04.2021 / 09:00
Positive preclinical
in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16
th Annual Huntington s Disease Therapeutics Conference
- Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington s disease pathology
- Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s .
AFFiRiS AGApril 27, 2021 GMT
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology
Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance Results set the ground for AFFiRiS’ potential first-in-class antibody-based systemic therapeutic modalities targeting mtHTT directly
VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington s Disease Therapeutics Conference
April 27, 2021 03:00 ET | Source: AFFiRiS AG AFFiRiS AG Vienna, AUSTRIA
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology
Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance
Results set the ground for AFFiRiS’ potential first-in-class antibody-based systemic therapeutic modalities targeting mtHTT directly
VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of
DGAP-News: AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16th Annual Huntington s Disease Therapeutics Conference boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.